Skip to the page

Data / Form D filings / Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc.: Form D filing

Jasper Therapeutics, Inc., a biotechnology company in Redwood City, CA, filed a Form D with the SEC in 2026. The latest, on August 5, 2026, reports $132 million sold of a $132 million offering to 40 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
2200 BRIDGE PKWY SUITE #102, Redwood City, CA, 94065
Phone
(650) 549-1400
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1788028

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Aug 5, 2026New notice$131,999,611$131,999,61140Jul 21, 2026sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Herb CrossExecutive Officer
Jeet MahalExecutive Officer, Director
Patrick CrutcherDirector
Thomas WiggansDirector
Judith ShizuruDirector
Svetlana LucasDirector
Kurt von EmsterDirector
Wenru SongExecutive Officer
Gregory F. KeenanExecutive Officer
Matthew E. RosDirector

Other biotechnology companies in California that filed recently

Every Form D from the week of Aug 3, 2026 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Jasper Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.